These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24865642)

  • 1. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania.
    Schachterle SE; Mtove G; Levens JP; Clemens E; Shi L; Raj A; Dumler JS; Munoz B; West S; Sullivan DJ
    Emerg Infect Dis; 2014 Jun; 20(6):941-9. PubMed ID: 24865642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
    Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
    Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
    Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azithromycin in control of trachoma.
    Schachter J; West SK; Mabey D; Dawson CR; Bobo L; Bailey R; Vitale S; Quinn TC; Sheta A; Sallam S; Mkocha H; Mabey D; Faal H
    Lancet; 1999 Aug; 354(9179):630-5. PubMed ID: 10466664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
    Yohannan J; He B; Wang J; Greene G; Schein Y; Mkocha H; Munoz B; Quinn TC; Gaydos C; West SK
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4144-50. PubMed ID: 24906862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania.
    Campbell JP; Mkocha H; Munoz B; West SK
    Ophthalmic Epidemiol; 2012 Feb; 19(1):38-42. PubMed ID: 22273357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping azithromycin mass drug administration for trachoma: A systematic review.
    Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands.
    Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC
    Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.
    Seidman JC; Coles CL; Silbergeld EK; Levens J; Mkocha H; Johnson LB; Muñoz B; West SK
    Int J Epidemiol; 2014 Aug; 43(4):1105-13. PubMed ID: 24659584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass treatment with single-dose azithromycin for trachoma.
    Solomon AW; Holland MJ; Alexander ND; Massae PA; Aguirre A; Natividad-Sancho A; Molina S; Safari S; Shao JF; Courtright P; Peeling RW; West SK; Bailey RL; Foster A; Mabey DC
    N Engl J Med; 2004 Nov; 351(19):1962-71. PubMed ID: 15525721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review.
    O'Brien KS; Emerson P; Hooper PJ; Reingold AL; Dennis EG; Keenan JD; Lietman TM; Oldenburg CE
    Lancet Infect Dis; 2019 Jan; 19(1):e14-e25. PubMed ID: 30292480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
    Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.